Prostamax

Reference-name product · exact chemical identity not independently confirmed

Lot-specific release specification; do not assign KEDP purity until the batch identity, supplied form, chromatographic purity and quantitative peptide content are confirmed · target, verify batch COACAS 473578-47-1RUO

Research statusLimited research; no major-market finished-drug approval identified

Supplied formPeptide reference material

Lead timeConfirmed with quote

Prostamax — White to off-white lyophilized material; confirm composition and lot appearance on the batch COA

Prostamax — White to off-white lyophilized material; confirm composition and lot appearance on the batch COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

A defined PubChem reference structure is available for KEDP identity comparison.
The page separates reference-name evidence from batch-level composition claims.
Review the matching batch COA first; scope additional sequence or supplied-form evidence only when the buyer's written procedure requires it.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 473578-47-1
Formula: C₂₀H₃₃N₅O₉
Molecular weight: 487.5 g/mol
Appearance: White to off-white lyophilized material; confirm composition and lot appearance on the batch COA
Purity: Lot-specific release specification; do not assign KEDP purity until the batch identity, supplied form, chromatographic purity and quantitative peptide content are confirmed · target, verify batch COA
Storage: Follow the released-lot COA, SDS and validated stability data for the confirmed chemical entity, supplied form, container and intended assay. A trade name alone cannot establish temperature, light protection, freeze-thaw tolerance or solution hold time.
MOQ: On request
Lead time: Confirmed with quote

PubChem CID 9848296

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Prostamax

PubChem maps the reference name Prostamax to the KEDP tetrapeptide (Lys-Glu-Asp-Pro), CID 9848296. Because trade-name preparations may not be compositionally equivalent, buyers should treat the PubChem record as a reference identity and confirm that the offered lot actually matches KEDP by its COA and identity data.

KEDP short-peptide identity and sequence research
Chromatin and gene-expression model research reported in the limited literature

Mechanism context

The question the literature is testing

A small, older literature base discusses KEDP and related short peptides in chromatin and gene-expression models. This evidence does not establish clinical efficacy, tissue selectivity or equivalence between every product sold under the Prostamax trade name.

Evidence map

Research routes and exposure context

Evidence tierAnalytical / laboratory context

Research areaKhavinson bioregulators

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

No robust human safety dataset or validated clinical-use framework was identified.
Do not assume a trade-name preparation is chemically identical to KEDP without lot-specific analytical confirmation.

Interactions reported in the literature

No reliable combination or compatibility data were identified for a generic trade-name preparation.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Prostamax factory batch COAs

No factory batch COA is published for this product yet. Ask sales for the latest available document.

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

The COA should state whether the material is defined KEDP or a multi-component preparation and identify the supplied form.
For a KEDP claim, reconcile sequence, formula, molecular weight, intact mass, chromatographic purity, quantitative peptide content, counterion, water and residual solvents with PubChem CID 9848296 and lot data.
Bioburden, endotoxin and sterility are separate attributes and cannot be inferred from identity or HPLC area purity.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot COA, SDS and validated stability data for the confirmed chemical entity, supplied form, container and intended assay. A trade name alone cannot establish temperature, light protection, freeze-thaw tolerance or solution hold time.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

PubChem CID 9848296 for the KEDP reference structure.
Dzhokhadze et al. Georgian Med News. 2012. PMID 23221144; limited cell-model context.

01
Short-peptide chromatin research associated with the Prostamax/KEDP literature
Georgian Medical News / PubMed · 2012 · peer-reviewed cell-model research; limited direct product evidence
Open source
02
Prostamax (KEDP) — PubChem Compound Summary
PubChem, US National Library of Medicine · 2026 · authoritative chemical database
Open source

Product FAQ

Questions buyers ask about Prostamax

Does the name Prostamax prove that the supplied lot is KEDP?+

No. PubChem CID 9848296 maps the name Prostamax to the KEDP tetrapeptide H-Lys-Glu-Asp-Pro-OH, formula C₂₀H₃₃N₅O₉ and molecular weight 487.5 g/mol. That database reference is useful for comparison, but a trade name alone does not establish an offered lot's sequence, salt, purity or equivalence. The quote and COA must explicitly identify the supplied material, supported by orthogonal identity data.

What does the published Prostamax or KEDP evidence establish?+

The independently located literature is small and includes an older PubMed-indexed cell-model paper on short peptides and chromatin decondensation. It does not establish clinical efficacy, prostate selectivity, an approved indication or equivalence among all trade-name preparations. Treat vendor summaries and unindexed citations as leads to verify, not as released-lot evidence.

Which documents should be requested for first-lot qualification?+

Prostamax

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Prostamax

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Prostamax factory batch COAs

Ask for the current packet, not a generic certificate

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Short-peptide chromatin research associated with the Prostamax/KEDP literature

Prostamax (KEDP) — PubChem Compound Summary

Questions buyers ask about Prostamax

Compare adjacent molecules and documentation needs.

Vesugen

Cardiogen

Cartalax

Bronchogen